Last reviewed · How we verify
Intrapleurally Alteplase vs Intrapleurally Urokinase
Intrapleurally Alteplase vs Intrapleurally Urokinase is a Small molecule drug developed by Hospital Universitari Vall d'Hebron Research Institute. It is currently FDA-approved.
At a glance
| Generic name | Intrapleurally Alteplase vs Intrapleurally Urokinase |
|---|---|
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intrapleurally Alteplase vs Intrapleurally Urokinase CI brief — competitive landscape report
- Intrapleurally Alteplase vs Intrapleurally Urokinase updates RSS · CI watch RSS
- Hospital Universitari Vall d'Hebron Research Institute portfolio CI
Frequently asked questions about Intrapleurally Alteplase vs Intrapleurally Urokinase
What is Intrapleurally Alteplase vs Intrapleurally Urokinase?
Intrapleurally Alteplase vs Intrapleurally Urokinase is a Small molecule drug developed by Hospital Universitari Vall d'Hebron Research Institute.
Who makes Intrapleurally Alteplase vs Intrapleurally Urokinase?
Intrapleurally Alteplase vs Intrapleurally Urokinase is developed and marketed by Hospital Universitari Vall d'Hebron Research Institute (see full Hospital Universitari Vall d'Hebron Research Institute pipeline at /company/hospital-universitari-vall-d-hebron-research-institute).
What development phase is Intrapleurally Alteplase vs Intrapleurally Urokinase in?
Intrapleurally Alteplase vs Intrapleurally Urokinase is FDA-approved (marketed).